LCL-161 is under clinical development by Novartis and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to GlobalData, Phase II drugs for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LCL-161’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LCL-161 is under development for the treatment of primary myelofibrosis, post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocytosis myelofibrosis. The drug candidate is administered orally as a tablet. It is a small molecule and targets apoptosis protein (IAP) family members: XIAP, cIAP1 and cIAP2. It was also under development for the treatment of advanced solid tumors such as triple negative breast cancer, metastatic pancreatic cancer, small cell lung cancer, epithelial ovarian cancer, fallopian tube cancer and peritoneal cancer, relapsed or refractory multiple myeloma.
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
For a complete picture of LCL-161’s drug-specific PTSR and LoA scores, buy the report here.